More than two years after the Food and Drug Administration held a public workshop on measuring overall survival (OS) in ...

The FDA has freed Rocket Pharmaceuticals from a clinical hold, giving the gene therapy developer permission to take flight ...

Xoma Royalty is ravenous for biotechs, and the Bay Area licensing aggregator has found its next meal in Mural Oncology. | ...

Celldex has stopped development of barzolvolimab in eosinophilic esophagitis (EoE) despite meeting its primary endpoint in a ...

A team of scientists at the National Institutes of Health used gene editing to fix the mutation that causes a form of the rare Tay-Sachs disease in mice, sparking hope that the approach could also ...

Partnering with VantAI could give Halda a source of target-effector pairs for its next wave of prospects. The deal could be ...

CSL is laying off up to 15% of its workforce as the Australian pharma looks to cut R&D costs and spin out its vaccine ...

Opthea’s options may be shrinking as the eye disease biotech comes to terms with a pair of phase 3 failures, but the company ...

In an update to their guidelines for treating high blood pressure, a group of cardiovascular medical societies has included a ...

Medtronic has agreed to not only expand the size of its board of directors, but to also task it with taking a closer look at ...

Gene therapy biotech Kriya Therapeutics has secured $313 million in a new series fundraise. | Gene therapy biotech Kriya ...

Genentech is continuing its summer of downsizing and cost-cutting, this time with plans to terminate a cell therapy deal ...